Polish OTC market to grow 7% year on year in 2015, bolstered by higher incidence of flu

25 August 2015

Although various stakeholders are invested in limiting the availability of over-the-counter (OTC) products, the OTC market in Poland will grow by nearly 7% year-on-year in 2015, says market research firm PMR.

In the next few years the market will continue to grow and move towards the concept of a beauty supply store merged with a pharmacy, or the establishment of parapharmacies. Polish market players are currently testing the hybrid health-beauty stores such as Super-Pharm or parapharmacies like Ziko, which offer primarily OTC medications and are not registered as pharmacies so are not subject to restrictions on advertising.

Many companies are looking to expand their OTC product portfolio in the future and are already involved in research in this domain. Consumers and health care practitioners do not eagerly accept equivalents of those already on the market, but unique products with clinically confirmed effects can translate to higher sales, if accompanied by strong marketing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >